MedTrace Logo

Hematopoietic Stem Cell Microtransplantation for in AML

NCT02676856 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-12-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of hematopoietic stem cell microtransplantation for in acute myeloid leukemia (AML)patients who can not receive hematopoietic stem cell transplantation (HSCT).

Conditions

Interventions

PROCEDURE

hematopoietic stem cell microtransplantation-long-term

Stem cell infusion are administrated once three months for 3 times with the cell count of 3\*10\^8/kg/once.

PROCEDURE

hematopoietic stem cell microtransplantation-short-term

Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3\*10\^8/kg/once.

DRUG

Conditioning for CR group

For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).

DRUG

Conditioning for Non-CR group

For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).

Sponsors & Collaborators

  • Guangzhou First People's Hospital

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • Peking University People's Hospital

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Zhujiang Hospital

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Qifa Liu · Nanfang Hospital, Southern Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-02-28
Completion
2018-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02676856 on ClinicalTrials.gov